Patient and disease characteristics: myeloablative regimens
| . | Donor type . | . | |
|---|---|---|---|
| Variable . | Haploidentical . | Unrelated . | P . |
| Number | 104 | 1245 | |
| Age, y | .94 | ||
| 21-50 | 60 (58%) | 709 (57%) | |
| 51-70 | 44 (42%) | 536 (43%) | |
| Sex, male | 47 (45%) | 631 (51%) | .28 |
| Performance score | .002 | ||
| 90-100 | 48 (46%) | 787 (63%) | |
| ≤80 | 50 (48%) | 425 (34%) | |
| Not reported | 6 (6%) | 33 (3%) | |
| Recipient CMV serostatus | .56 | ||
| Positive | 48 (46%) | 786 (63%) | |
| Negative | 23 (22%) | 438 (35%) | |
| Not reported | 33 (32%) | 21 (2%) | |
| Disease status at transplantation | .13 | ||
| First complete remission | 48 (46%) | 786 (63%) | |
| Second complete remission | 21 (20%) | 255 (20%) | |
| Relapse | 35 (34%) | 310 (25%) | |
| Disease risk index | .62 | ||
| Low risk index | 5 (5%) | 62 (5%) | |
| Intermediate risk index | 66 (63%) | 843 (68%) | |
| High risk index | 33 (32%) | 340 (27%) | |
| Secondary AML | 17 (16%) | 179 (14%) | .58 |
| De novo AML | 87 (84%) | 1066 (86%) | — |
| Cytogenetics* | .01 | ||
| Favorable | 12 (12%) | 74 (6%) | |
| Intermediate | 66 (63%) | 951 (76%) | |
| Adverse | 23 (22%) | 178 (14%) | |
| Not reported | 3 (3%) | 42 (3%) | |
| Conditioning regimen | N/A† | ||
| TBI + cyclophosphamide | 3 (3%) | 324 (26%) | |
| TBI + fludarabine | 20 (19%) | — | |
| Busulfan + cyclophosphamide | 45 (43%) | 401 (32%) | |
| Melphalan + thiotepa + fludarabine | 23 (22%) | — | |
| Busulfan + fludarabine | — | 233 (19%) | |
| Busulfan + fludarabine + ATG | — | 287 (23%) | |
| Busulfan + thiotepa + fludarabine | 13 (13%) | — | |
| GVHD prophylaxis | N/A† | ||
| Tacrolimus/CSA + MMF | 100 (96%) | 114 (9%) | |
| Tacrolimus/CSA + MTX | — | 1048 (84%) | |
| Tacrolimus/CSA + sirolimus | — | 83 (7%) | |
| Posttransplant cyclophosphamide | 104 (100%) | — | |
| Graft type | <.001 | ||
| BM | 85 (82%) | 231(19%) | |
| Peripheral blood | 19 (18%) | 1014 (81%) | |
| Interval between diagnosis and transplant | .82 | ||
| ≤12 mo | 80 (77%) | 970 (78%) | |
| >12 mo | 24 (23%) | 275 (22%) | |
| Transplant period | <.001 | ||
| 2009-2010 | 25 (24%) | 578 (47%) | |
| 2011-2012 | 79 (76%) | 667 (53%) | |
| Follow up, median (range), mo | 30 (7-59) | 36 (9 -64) | |
| . | Donor type . | . | |
|---|---|---|---|
| Variable . | Haploidentical . | Unrelated . | P . |
| Number | 104 | 1245 | |
| Age, y | .94 | ||
| 21-50 | 60 (58%) | 709 (57%) | |
| 51-70 | 44 (42%) | 536 (43%) | |
| Sex, male | 47 (45%) | 631 (51%) | .28 |
| Performance score | .002 | ||
| 90-100 | 48 (46%) | 787 (63%) | |
| ≤80 | 50 (48%) | 425 (34%) | |
| Not reported | 6 (6%) | 33 (3%) | |
| Recipient CMV serostatus | .56 | ||
| Positive | 48 (46%) | 786 (63%) | |
| Negative | 23 (22%) | 438 (35%) | |
| Not reported | 33 (32%) | 21 (2%) | |
| Disease status at transplantation | .13 | ||
| First complete remission | 48 (46%) | 786 (63%) | |
| Second complete remission | 21 (20%) | 255 (20%) | |
| Relapse | 35 (34%) | 310 (25%) | |
| Disease risk index | .62 | ||
| Low risk index | 5 (5%) | 62 (5%) | |
| Intermediate risk index | 66 (63%) | 843 (68%) | |
| High risk index | 33 (32%) | 340 (27%) | |
| Secondary AML | 17 (16%) | 179 (14%) | .58 |
| De novo AML | 87 (84%) | 1066 (86%) | — |
| Cytogenetics* | .01 | ||
| Favorable | 12 (12%) | 74 (6%) | |
| Intermediate | 66 (63%) | 951 (76%) | |
| Adverse | 23 (22%) | 178 (14%) | |
| Not reported | 3 (3%) | 42 (3%) | |
| Conditioning regimen | N/A† | ||
| TBI + cyclophosphamide | 3 (3%) | 324 (26%) | |
| TBI + fludarabine | 20 (19%) | — | |
| Busulfan + cyclophosphamide | 45 (43%) | 401 (32%) | |
| Melphalan + thiotepa + fludarabine | 23 (22%) | — | |
| Busulfan + fludarabine | — | 233 (19%) | |
| Busulfan + fludarabine + ATG | — | 287 (23%) | |
| Busulfan + thiotepa + fludarabine | 13 (13%) | — | |
| GVHD prophylaxis | N/A† | ||
| Tacrolimus/CSA + MMF | 100 (96%) | 114 (9%) | |
| Tacrolimus/CSA + MTX | — | 1048 (84%) | |
| Tacrolimus/CSA + sirolimus | — | 83 (7%) | |
| Posttransplant cyclophosphamide | 104 (100%) | — | |
| Graft type | <.001 | ||
| BM | 85 (82%) | 231(19%) | |
| Peripheral blood | 19 (18%) | 1014 (81%) | |
| Interval between diagnosis and transplant | .82 | ||
| ≤12 mo | 80 (77%) | 970 (78%) | |
| >12 mo | 24 (23%) | 275 (22%) | |
| Transplant period | <.001 | ||
| 2009-2010 | 25 (24%) | 578 (47%) | |
| 2011-2012 | 79 (76%) | 667 (53%) | |
| Follow up, median (range), mo | 30 (7-59) | 36 (9 -64) | |
ATG, anti-thymocyte globulin; CMV, cytomegalovirus; CSA, cyclosporine; MMF, mycophenolate; MTX, methotrexate.
Favorable = t(8;21); inv(16) and t(15;17); adverse = complex karyotypes ≥4 abnormalities; intermediate = all others.
N/A = not applicable; P-values are not shown as conditioning regimens and GVHD prophylaxis are “packages” and therefore differ by donor source.